Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 known ✓ | O75116 | 2/20 | 0.51 |
| ▸ | ROCK1 known ✓ | Q13464 | 2/20 | 0.51 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.46 |
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.44 |
| ▸ | DRD1 known ✓ | P21728 | 1/20 | 0.44 |
| ▸ | ANPEP | P15144 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | RXRA | P19793 | 2/20 | 0.45 |
| ▸ | RXRB | P28702 | 2/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | RXRG | P48443 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA3 | P07451 | 1/20 | 0.44 |
| ▸ | TYR | P14679 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2406930 | 1.00 | ANPEP (0.55) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL4532593 | 1.00 | ANPEP (0.55) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Terephthalic Acid SCHEMBL8743590 | 0.98 | ANPEP (0.57) | ANPEPTSHRTP53ROCK2ROCK1 | |
| SCHEMBL2129856 | 0.98 | ANPEP (0.57) | ANPEPTSHRTP53ROCK2ROCK1 | |
| SCHEMBL4878931 | 0.98 | ANPEP (0.57) | ANPEPTSHRTP53ROCK2ROCK1 | |
| SCHEMBL4448319 | 0.98 | ANPEP (0.57) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Sulfuric Acid SCHEMBL3913765 | 0.90 | ANPEP (0.50) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Sulfuric Acid SCHEMBL2295357 | 0.90 | ANPEP (0.50) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Sulfuric Acid SCHEMBL3917965 | 0.90 | ANPEP (0.50) | ANPEPTSHRTP53ROCK2ROCK1 | |
| Benzoic Acid SCHEMBL28384787 | 0.85 | DAO (0.58) | ANPEPTSHRALDH1A1SMN1; SMN2SRD5A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024028604-A1 | MORPHOLINE-3-CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN E2 RECEPTOR 4 (EP4) AGONISTS FOR THE TREATMENT OF GASTROINTESTINAL AND PULMONARY DISEASES | HEPTARES THERAPEUTICS LIMITED (GB) | 2024-02-08 | — | — | WO | disclosed |
| EP-3362454-B1 | EP4 ANTAGONISTS | EISAI R&D MAN CO LTD (JP) | 2021-12-08 | — | — | EP | disclosed |
| US-20210347779-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-11-11 | — | — | US | disclosed |
| US-10941148-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-03-09 | — | — | US | disclosed |
| US-20190315754-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-10-17 | — | — | US | disclosed |
| US-10316040-B2 | EP4 antagonists | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-06-11 | — | — | US | disclosed |
| US-10166301-B2 | Chelated PSMA inhibitors | CANCER TARGETED TECHNOLOGY LLC (US) | 2019-01-01 | — | — | US | disclosed |
| US-20180305362-A1 | EP4 ANTAGONISTS | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2018-10-25 | — | — | US | disclosed |
| CN-108473497-A | Ep4 antagonists | 卫材R&D 管理有限公司 | 2018-08-31 | — | — | CN | disclosed |
| EP-3362454-A1 | EP4 ANTAGONISTS | Eisai R&D Management Co., Ltd. (JP) | 2018-08-22 | — | — | EP | disclosed |
| EP-2350020-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION | 2011-07-21 | — | — | US | disclosed |
| WO-2010039789-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2010-04-08 | — | — | WO | disclosed |
| EP-1663979-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-0915700-B1 | USE OF BETA-SHEET MIMETICS AS PROTEASE AND KINASE INHIBITORS AND AS INHIBITORS OF TRANSCRIPTION FACTORS | MYRIAD GENETICS INC (US) | 2006-03-22 | — | — | EP | disclosed |
| WO-2005021508-A1 | PHENYL OR PYRIDYL AMIDE COMPOUNDS AS PROSTAGLANDIN E2 ANTAGONISTS | PFIZER INC. (US) | 2005-03-10 | — | — | WO | disclosed |
| EP-0386839-B1 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME (GB) | 1997-01-15 | — | — | EP | disclosed |
| US-5231102-A | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME, LTD. (GB) | 1993-07-27 | — | — | US | disclosed |
| EP-0386839-A2 | Tetrahydroquinoline derivatives useful for neurodegenerative disorders | MERCK SHARP & DOHME LTD. (GB) | 1990-09-12 | — | — | EP | disclosed |
| CN-86108626-A | Phenylformic acid and benzoate derivatives with anti-inflammatory and pain palliation efficacy | — | 1987-07-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10166301-B2 | Chelated PSMA inhibitors | FOLH1, KLK3, PSMA1 | ROCK2 3160/4885ROCK1 2045/4885ADRB2 2761/4885 |
| US-20180305362-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | ROCK2 1557/4885ROCK1 1776/4885ADRB2 72/4885 |
| US-10316040-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | ROCK2 1557/4885ROCK1 1776/4885ADRB2 72/4885 |
| US-10941148-B2 | EP4 antagonists | PTGER4, PTGER3, PTGER1 | ROCK2 1557/4885ROCK1 1776/4885ADRB2 72/4885 |
| US-20110178007-A1 | SPIRO-IMIDAZOLONE DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS | GLP1R, GCGR, GIPR | ROCK2 1054/4885ROCK1 1382/4885ADRB2 26/4885 |
| US-20190315754-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | ROCK2 1557/4885ROCK1 1776/4885ADRB2 72/4885 |
| US-20210347779-A1 | EP4 ANTAGONISTS | PTGER4, PTGER3, PTGER1 | ROCK2 1557/4885ROCK1 1776/4885ADRB2 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.